Physician profile
Imad Bagh
NPI 1902112006
$6,050.40
in general payments reported to CMS, 2019-2025
28 companies · $673 in 2025
The $673 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $151 · 2021: $167 · 2022: $297 · 2023: $3,902 · 2024: $743 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,901 · Travel and Lodging: $2,416 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,901.41 |
| Travel and Lodging | $2,416.21 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,234.64 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Abbott Laboratories | $1,711.78 | 2023-2025 | Mitraclip, Supera, Portico |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $255.14 | 2020-2024 | Lifevest |
| Novo Nordisk INC | $221.31 | 2023-2024 | |
| Pfizer INC. | $164.93 | 2022-2025 | |
| Boston Scientific Corporation | $164.19 | 2021-2025 | Watchman Flx |
| Philips North America LLC | $148.04 | 2022 | |
| Medtronic, INC. | $136.17 | 2024-2025 | Corevalve Evolut R |
| E.R. Squibb & Sons, L.L.C. | $136.09 | 2021-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $100.10 | 2024-2025 | |
| Astellas Pharma US INC | $99.00 | 2019 | |
| Amgen INC. | $98.16 | 2021-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $85.49 | 2023-2024 | Xarelto |
| Lantheus Medical Imaging, INC. | $83.43 | 2020-2022 | |
| Shockwave Medical, INC | $77.39 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $67.22 | 2023-2025 | Farxiga, Wainua |
| Alnylam Pharmaceuticals INC. | $37.10 | 2024 | Onpattro |
| Medtronic Vascular, INC. | $34.39 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $32.38 | 2025 | Opsumit, Uptravi |
| Biosense Webster, INC. | $26.18 | 2025 | Na |
| Kiniksa Pharmaceuticals International, Plc | $21.43 | 2024 | Arcalyst |
| Siemens Medical Solutions USA, INC. | $18.96 | 2023 | Corpath Imaging System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.89 | 2022 | |
| Biotronik INC. | $18.49 | 2022 | |
| United Therapeutics Corporation | $17.08 | 2025 | Tyvaso |
| Abiomed | $14.62 | 2025 | |
| Chiesi USA, INC. | $13.91 | 2025 | Kengreal, Cleviprex |
| Merck Sharp & Dohme LLC | $13.89 | 2024 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imad Bagh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.